在常见的人类GCKR变异的小鼠模型中,AZD1656葡萄糖激酶激活剂的慢性疗效受损
Brian E Ford1, Shruti S Chachra1, Ahmed Alshawi2
1Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Biochemical pharmacology
|August 22, 2024
概括
葡萄糖激酶激活剂 (GKA) 在2型糖尿病治疗中随着时间的推移而失去有效性. 肝糖激酶调节蛋白 (GKRP) 缺乏会加剧这种衰退,并可能增加肝脂,影响药物的疗效.
科学领域:
- 代谢性疾病是一种代谢性疾病.
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 葡萄糖激酶激活剂 (GKA) 已开发用于2型糖尿病,但显示慢性疗效下降.
- 这种功效丧失背后的机制尚未完全理解.
- 常见的人类GCKR变异可能导致肝脏葡萄酶调节蛋白 (GKRP) 缺乏.
研究的目的:
- 调查GKRP缺乏是否会影响慢性GKA疗效.
- 检查GCKR变异对GKA反应的影响.
- 了解GKA疗效下降的分子机制.
主要方法:
- 利用Gckr-P446L和Gckr-del/wt小鼠模型来模仿人类的GKRP缺乏.
- 长期使用GKA AZD1656,以评估降血糖效果.
- 分析了肝脏葡萄酶活性,肝脏脂质和肝脏转录组.
主要成果:
- 在Gckr-P446L小鼠中,在LL基因型中,AZD1656的有效性在19周后下降,肝脏葡萄酶活性增加.
- 在野生型小鼠中,持续的GKA疗效与适度的肝脏转录组变化相关.
- 在Gckr-del/wt小鼠中,慢性AZD1656治疗导致肝脏甘油三酸和脂肪升.
结论:
- 与常见的 GCKR 变体相关的 GKRP 缺乏症会导致 GKA 在降低血糖的有效性下降.
- 经过慢性GKA治疗,GKRP缺乏会导致肝脂增加和脂肪.
- 了解GKRP的作用对于开发2型糖尿病有效的长期GKA疗法至关重要.
相关概念视频
01:16In-vitro Mutagenesis
13.9K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
13.9K
02:43Mouse Models of Cancer Study
5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K